Donovan Quill, President and CEO, Optime Care, article featured on July 19, 2021.
Rare diseases affect 1% or less of the global population, with the geographic spread and small number of those impacted makes the cost of research and development prohibitive and leaves patients without treatments. Of the 7,000 known rare diseases, 95% do not have a single FDA-approved drug treatment.
Clinical research professionals seeking to build a go-to market strategy may feel overwhelmed about where to start and may be tempted to revert to a so-called “pharma strategy expert.” This term is misleading, given that it’s impossible to provide expertise across the wide range of therapies for rare and orphan conditions. Each patient is unique in terms of treatment, points of care, physicians and level of caregiving they require.
This article discusses how the care management solution should meet the needs of everyone involved in the patient’s journey, from clinical research professionals and specialty drug manufacturers to pharmacists, caregivers and physicians.
